Certara provided expertise, including governance committee membership, leadership of clinical pharmacology and pharmacometrics, and support for translational medicine, regulatory science, and strategy activities. Certara’s approach yielded a significant financial, scientific, and regulatory ROI to MDGH, culminating in FDA approval and receipt of a tropical disease priority review voucher.